EPREX®; EPIAO®
A Prospective, Randomized, Double Blind, Parallel Group Study to Evaluate a 1:1 Dose Conversion From EPREX to EPIAO in Term of Clinical Efficacy and Safety in Subjects With End-Stage Renal Disease on Haemodialysis
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT02947438/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 207 чел. во всех странах исследования.
- Центров в реестре: 11 в 5 городах. Список — ниже на странице.
- Плановая дата окончания (10.2021) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 18
Критерии включения
- Male and female subjects between the age of 18 to 75 years
- Subjects with end stage renal disease (CKD stage 5) on hemodialysis and on epoetin treatment for at least 3 months prior to screening
- Subjects with haemoglobin between 10 g/dl to 12 g/dl
- Subjects who are on clinically stable haemodialysis (defined as no clinically relevant changes of dialysis regimen and/or dialyzer) for at least 3 months prior to screening
- Subjects willing to provide a written informed consent
- Subjects with serum ferritin ≥ 200 μg/L and/or transferrin saturation ≥ 20%
- Subjects with a life expectancy of more than at least study period in clinical judgment of the investigator
Критерии невключения
- Subjects with anaemia due to other reasons (that is not renal anaemia)
- Subjects who have undergone blood transfusion within the last 3 months
- Subjects with major complication such as severe/chronic infections or bleeding or aluminum toxicity
- Subjects with suspected or known pure red cell aplasia (PRCA)
- Subjects with a history of aplastic anaemia
- Subjects with uncontrolled diabetes (fasting blood glucose > 240 mg/dl) or uncontrolled hypertension (systolic blood pressure > 180 mm Hg, diastolic blood pressure > 110 mm Hg)
- Subjects with known hypersensitivity to any of the ingredients of the investigational products, the mammalian cell-derived product or human albumin products
- Subjects with history of seizure disorder
- Subjects with hematological disorder
- Subjects with hyperparathyroidism
- Subjects with congestive heart failure and/or angina (NYHA class III and IV)
- Subjects with myocardial infarction or stroke in the preceding 6 months of screening
- Subjects with active malignancy in the previous 5 years
- Subjects with gastrointestinal bleeding in the past 6 months
- Subjects with immunosuppressive therapy in the previous 3 months
- Subjects with active hepatitis B virus (HBsAg) (positive for HBsAg and IgM anti-HBc) and hepatitis C virus (HCV) (positive for Anti-HCV antibody) and human immunodeficiency virus (HIV)
- Female subjects who are pregnant, breast-feeding, planning to be pregnant during the study, or women of child-bearing potential (any woman who is not surgically sterile i.e. bilateral tubal ligation, total hysterectomy or < 2 years post menopause) not using a reliable method of double contraception (e.g. condom plus diaphragm, condom or diaphragm plus spermicidal gel/foam, tubal ligation, or stable dose of hormonal contraception) throughout the study period
- Subjects participating in trials involving erythropoietin in the past 6 months before screening.Subjects currently participating or participation in an investigational study within 30 days prior screening
Источник: ClinicalTrials.gov, NCT02947438 · запись обновлена в реестре 23 ноября 2022.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 4
- Mean absolute change in haemoglobin level from baseline to 6 months — from baseline to 6 months
- Mean absolute change in weekly epoetin dosage per kg body weight from baseline to 6 months — from baseline to 6 months
Цель исследования
This study is aimed to comprehensively establish the bio-similarity/bioequivalence in EPIAO® and EPREX® in terms of 52-week comparisons in efficacy, safety and immunogenicity. The targeted population is anaemia patients with end-stage chronic renal disease who previously received epoetin treatment and on haemodialysis.
Где проходит
11 центров в 5 городах- State Budgetary Healthcare Institution of the Republic of Karelia «V.A. Baranov Republican Hospital»
- State budgetary healthcare institution of Moscow region «Moscow Regional Scientific Research and Clinical Institute named after M.F.Vladimirsky», Department of Transplantation, nephrology and surgical hemocorrection
- North-Western State Medical University named after I. I. Mechnikov
- St. Petersburg State Medical Institution: Municipal Hospital of St. Elizabeth
- State budgetary institution «St-Petersburg' scientific-research institution of emergency n.a Dzanelidze)»
- The Federal State Budgetary Institute «The Nikiforov Russian Center of Emergency and Radiation Medicine» of the Ministry of Russian Federation for Civil Defense, Emergencies and Elimination of Consequences of Natural Disasters
- СПб ГБУЗ «Городская Мариинская больница»
- СПб ГБУЗ «Городская больница № 15»
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02947438 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.